Timothy E Wilens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5148022/publications.pdf

Version: 2024-02-01

286 papers

23,086 citations

81 h-index 10399 144 g-index

288 all docs

288 docs citations

times ranked

288

12196 citing authors

#	Article	IF	CITATIONS
1	The Relationship Between Cannabis Use and Self-Reported Trait Anger in Treatment-Seeking Young People. Cannabis and Cannabinoid Research, 2024, 9, 223-229.	1.5	1
2	Decreased risk for substance use disorders in individuals with high-functioning autism spectrum disorder. European Child and Adolescent Psychiatry, 2023, 32, 257-265.	2.8	4
3	Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate. Journal of Attention Disorders, 2022, 26, 696-705.	1.5	7
4	A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Research, 2022, 308, 114347.	1.7	21
5	"You have to take this medication, but then you get punished for taking it:―lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period. Journal of Substance Abuse Treatment, 2022, 139, 108765.	1.5	26
6	Characterizing autistic traits in treatmentâ€seeking young adults with substance use disorders. American Journal on Addictions, 2022, 31, 108-114.	1.3	4
7	Cardiovascular Considerations for Stimulant Class Medications. Child and Adolescent Psychiatric Clinics of North America, 2022, , .	1.0	O
8	ADHD and Substance Use Disorders in Young People. Child and Adolescent Psychiatric Clinics of North America, 2022, , .	1.0	5
9	The Impact of Pharmacotherapy of Childhood-Onset Psychiatric Disorders on the Development of Substance Use Disorders. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 200-214.	0.7	6
10	Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress. Journal of Attention Disorders, 2021, 25, 340-354.	1.5	13
11	Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder and Retention in Outpatient Substance Use Disorder Treatment. Journal of Clinical Psychiatry, 2021, 82, .	1.1	11
12	Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. American Journal of Obstetrics and Gynecology, 2021, 225, 424.e1-424.e12.	0.7	32
13	Psychiatric comorbidity associated with co-occurring autism spectrum disorder and substance use disorder. Research in Autism Spectrum Disorders, 2021, 82, 101728.	0.8	2
14	Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics. JAMA Network Open, 2021, 4, e2110721.	2.8	33
15	Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature. Journal of Psychopharmacology, 2021, 35, 203-210.	2.0	13
16	The Prevalence of Unhealthy Alcohol and Drug use among Inpatients in a General Hospital. Substance Abuse, 2020, 41, 331-339.	1.1	18
17	Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery. Addiction, 2020, 115, 291-301.	1.7	36
18	Editorial: Stimulants: Friend or Foe?. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 36-37.	0.3	5

#	Article	IF	CITATIONS
19	Prior Authorizations: A Necessary Evil?. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 1005-1007.	0.3	1
20	Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts. JAMA Network Open, 2020, 3, e205734.	2.8	115
21	High Correspondence Between Child Behavior Checklist Rule Breaking Behavior Scale with Conduct Disorder in Males and Females. Child Psychiatry and Human Development, 2020, 51, 978-985.	1.1	2
22	IMPROVING MEASURES OF DYADIC OUTCOMES IN PERINATAL SUBSTANCE USE RESEARCH. Addiction, 2020, 115, 1787-1788.	1.7	1
23	A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. Journal of Psychiatric Research, 2020, 123, 21-30.	1.5	113
24	Disentangling the Social Context of Nonmedical Use of Prescription Stimulants in College Students. American Journal on Addictions, 2020, 29, 476-484.	1.3	4
25	Literature review: Substance use screening and co-morbidity in medically hospitalized youth. General Hospital Psychiatry, 2020, 67, 115-126.	1.2	4
26	Differences in Prescription Stimulant Misuse Motives Across Adolescents and Young Adults in the United States. Journal of Clinical Psychiatry, 2020, 81, .	1.1	5
27	Differences in Prescription Stimulant Misuse Motives Across Adolescents and Young Adults in the United States. Journal of Clinical Psychiatry, 2020, 81, .	1.1	11
28	Risk Factors for Overdose in Young People Who Received Substance Use Disorder Treatment. American Journal on Addictions, 2019, 28, 382-389.	1.3	8
29	Risk Factors for Drug Overdose in Young People: A Systematic Review of the Literature. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 487-497.	0.7	50
30	Prevalence and Consequences of the Nonmedical Use of Amphetamine Among Persons Calling Poison Control Centers. Journal of Attention Disorders, 2019, 23, 1219-1228.	1.5	21
31	Sources of Nonmedical Prescription Drug Misuse Among US High School Seniors: Differences in Motives and Substance Use Behaviors. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 681-691.	0.3	30
32	Use of Phenobarbital in Alcohol Withdrawal Management – A Retrospective Comparison Study of Phenobarbital and Benzodiazepines for Acute Alcohol Withdrawal Management in General Medical Patients. Psychosomatics, 2019, 60, 458-467.	2.5	52
33	Prescription Drug Misuse: Sources of Controlled Medications in Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 670-680.e4.	0.3	35
34	Very early family-based intervention for anxiety: two case studies with toddlers. Annals of General Psychiatry, 2019, 32, e100156.	1.1	2
35	Prescription Stimulants. Pediatric Clinics of North America, 2019, 66, 1109-1120.	0.9	13
36	Considerations for Treating Young People With Comorbid Autism Spectrum Disorder and Substance Use Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 1139-1141.	0.3	13

3

#	Article	IF	CITATIONS
37	Age-specific risk of substance use disorders associated with controlled medication use and misuse subtypes in the United States. Addictive Behaviors, 2019, 90, 285-293.	1.7	40
38	Further evidence of the Diagnostic Utility of the Child Behavior Checklist for identifying pediatric Bipolar I Disorder. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 2019, 7, 1-8.	0.3	7
39	Functional Impairment in Youth With ADHD. Journal of Clinical Psychiatry, 2019, 81, .	1.1	7
40	Reliability and Validity of the Before-School Functioning Scale in Children With ADHD. Journal of Attention Disorders, 2018, 22, 1040-1048.	1.5	12
41	Does exposure to parental substance use disorders increase offspring risk for a substance use disorder? A longitudinal follow-up study into young adulthood. Drug and Alcohol Dependence, 2018, 186, 154-158.	1.6	18
42	128 Effect of DR/ER-MPH on Early Morning and Late Afternoon/Evening Functioning in Children With ADHD: Analysis of PREMB-R Items From a Phase 3 Trial. CNS Spectrums, 2018, 23, 80-81.	0.7	1
43	Neuropsychological changes in patients with substance use disorder after completion of a one month intensive outpatient treatment program. American Journal on Addictions, 2018, 27, 632-638.	1.3	7
44	129 Effect of DR/ER-MPH on Caregiver-Reported ADHD Symptom Improvement in Children With ADHD and Caregiver Strain: Results From a Phase 3 Trial. CNS Spectrums, 2018, 23, 81-81.	0.7	1
45	Attention-Deficit/Hyperactivity Disorder and Transitional Aged Youth. Current Psychiatry Reports, 2018, 20, 100.	2.1	20
46	130 Consistent Efficacy of DR/ER-MPH on Early Morning Functioning in Children With ADHD: Analysis of BSFQ Item Ratings From a Pivotal Phase 3 Trial. CNS Spectrums, 2018, 23, 82-82.	0.7	0
47	Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. Journal of Affective Disorders, 2018, 238, 244-249.	2.0	8
48	Opioid Use Disorders in Adolescents—Updates in Assessment and Management. Current Pediatrics Reports, 2018, 6, 99-106.	1.7	20
49	Risk Factors for Overdose in Treatment-Seeking Youth With Substance Use Disorders. Journal of Clinical Psychiatry, 2018, 79, .	1.1	19
50	Sources of Prescription Medication Misuse Among Young Adults in the United States. Journal of Clinical Psychiatry, 2018, 79, 33-40.	1.1	60
51	The Co-Occurrence of ADHD and Substance Use Disorders. Psychiatric Annals, 2018, 48, 328-332.	0.1	9
52	Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD. Journal of Attention Disorders, 2017, 21, 110-119.	1.5	16
53	Neuropsychological functioning in college students who misuse prescription stimulants. American Journal on Addictions, 2017, 26, 379-387.	1.3	32
54	Adolescents' Prescription Stimulant Use and Adult Functional Outcomes: A National Prospective Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 226-233.e4.	0.3	65

#	Article	IF	CITATIONS
55	Medical Cannabinoids in Children and Adolescents: A Systematic Review. Pediatrics, 2017, 140, .	1.0	103
56	Factors associated with attrition in substance using patients enrolled in an intensive outpatient program. American Journal on Addictions, 2017, 26, 780-787.	1.3	5
57	Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 474-482.	0.7	29
58	Pilot Data Supporting Omega-3 Fatty Acids Supplementation in Medicated Children with Attention-Deficit/Hyperactivity Disorder and Deficits in Emotional Self-Regulation. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 755-756.	0.7	1
59	Examining the association between attention deficit hyperactivity disorder and substance use disorders: A familial risk analysis. Journal of Psychiatric Research, 2017, 85, 49-55.	1.5	18
60	3.29 Psychometric Validation of the Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior Scale, Revised in Children With Attention-Deficit/Hyperactivity Disorder (ADHD). Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, S212-S213.	0.3	1
61	Medical Marijuana in Children and Adolescents: An Updated Review for Psychopharmacologists. Child and Adolescent Psychopharmacology News, 2017, 22, 1-8,10.	0.1	1
62	Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 479-486.	0.3	58
63	Treatment of Comorbid Substance Use Disorders and ADHD in Youth. Current Treatment Options in Psychiatry, 2016, 3, 15-27.	0.7	4
64	Using a Brief Parent-Report Measure to Track Outcomes for Children and Teens with ADHD. Child Psychiatry and Human Development, 2016, 47, 407-416.	1.1	8
65	Predicting ADHD by Assessment of Rutter's Indicators of Adversity in Infancy. PLoS ONE, 2016, 11, e0157352.	1.1	32
66	Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder. Journal of Clinical Psychiatry, 2016, 77, 1420-1427.	1.1	29
67	Nonmedical Stimulant Use in College Students. Journal of Clinical Psychiatry, 2016, 77, 940-947.	1.1	27
68	College Students: Mental Health Problems and Treatment Considerations. Academic Psychiatry, 2015, 39, 503-511.	0.4	599
69	A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 916-925.e2.	0.3	51
70	Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. American Journal on Addictions, 2015, 24, 173-177.	1.3	62
71	Diagnosing ADHD in children and adults. , 2014, , 16-23.		6
72	Comorbidity of ADHD and anxiety disorders. , 2014, , 98-110.		5

#	Article	IF	Citations
73	The Complicated Relationship Between Attention Deficit/Hyperactivity Disorder and Substance Use Disorders. Current Psychiatry Reports, 2014, 16, 436.	2.1	143
74	Pediatric Psychopharmacology: Food and Drug Administration Approval Through the Evidence Lens. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 716-719.	0.3	3
75	Parental history of substance use disorders (SUD) and SUD in offspring: A controlled family study of bipolar disorder. American Journal on Addictions, 2014, 23, 440-446.	1.3	15
76	Conceptual issues in understanding comorbidity in ADHD. , 2014, , 63-71.		5
77	ADHD and learning disorders. , 2014, , 123-138.		1
78	Oppositional defiant disorder and conduct disorder. , 2014, , 139-149.		4
79	ADHD diagnostic and symptom assessment scales for adults. , 2014, , 224-232.		9
80	Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. American Journal on Addictions, 2014, 24, n/a-n/a.	1.3	4
81	Transitional Aged Youth: A New Frontier in Child and Adolescent Psychiatry. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 887-890.	0.3	65
82	Does exposure to parental substance use disorders increase substance use disorder risk in offspring? A 5â€year followâ€up study. American Journal on Addictions, 2013, 22, 460-465.	1.3	46
83	Difficulties in emotional regulation and substance use disorders: A controlled family study of bipolar adolescents. Drug and Alcohol Dependence, 2013, 132, 114-121.	1.6	44
84	A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World Journal of Biological Psychiatry, 2013, 14, 299-306.	1.3	14
85	Using Stimulants for Attention-Deficit/Hyperactivity Disorder. primary care companion for CNS disorders, The, 2013, 15, .	0.2	25
86	Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry, 2012, 2, 301-312.	0.4	39
87	A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 74-85.e2.	0.3	99
88	Atomoxetine Treatment Outcomes in Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: Results From a Post Hoc, Pooled Analysis. Clinical Therapeutics, 2012, 34, 363-373.	1.1	9
89	Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder?. Bipolar Disorders, 2012, 14, 507-514.	1.1	11
90	Randomized Controlled Study of the Histamine H3 Inverse Agonist MK-0249 in Adult Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2012, 73, e891-e898.	1.1	29

#	Article	IF	CITATIONS
91	A Sobering Fact: ADHD Leads to Substance Abuse. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 6-8.	0.3	21
92	Cardiovascular Risk of Stimulant Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder: Update and Clinical Recommendations. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 978-990.	0.3	73
93	Do Executive Function Deficits Predict Later Substance Use Disorders Among Adolescents and Young Adults?. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 141-149.	0.3	43
94	Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 73-84.e1.	0.3	34
95	Does ADHD Predict Substance-Use Disorders? A 10-Year Follow-up Study of Young Adults With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 543-553.	0.3	249
96	Impact of executive function deficits in youth with bipolar I disorder: A controlled study. Psychiatry Research, 2011, 186, 58-64.	1.7	35
97	The intersection of attention-deficit/hyperactivity disorder and substance abuse. Current Opinion in Psychiatry, 2011, 24, 280-285.	3.1	89
98	An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Review of Neurotherapeutics, 2011, 11, 1443-1465.	1.4	92
99	Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. Current Medical Research and Opinion, 2011, 27, 2309-2320.	0.9	46
100	Psychosocial Functioning, Familiality, and Psychiatric Comorbidity in Bipolar Youth With and Without Psychotic Features. Journal of Clinical Psychiatry, 2011, 72, 397-405.	1.1	31
101	Reasons for Substance Use among Adolescents with Bipolar Disorder. American Journal on Addictions, 2010, 19, 474-480.	1.3	19
102	Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood. Postgraduate Medicine, 2010, 122, 97-109.	0.9	203
103	Plasma Methylphenidate Concentrations in Youths Treated with High-Dose Osmotic Release Oral System Formulation. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 49-54.	0.7	17
104	Adult Psychiatric Outcomes of Girls With Attention Deficit Hyperactivity Disorder: 11-Year Follow-Up in a Longitudinal Case-Control Study. American Journal of Psychiatry, 2010, 167, 409-417.	4.0	219
105	A Controlled Trial of the Methylphenidate Transdermal System on Before-School Functioning in Children With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2010, 71, 548-556.	1.1	26
106	TDAH CON TRASTORNOS POR CONSUMO DE SUSTANCIAS. , 2010, , 249-263.		0
107	TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES. , 2010, , 339-384.		0
108	An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders. Journal of ADHD & Related Disorders, 2010, 1, 25-35.	0.5	8

#	Article	IF	Citations
109	Presenting ADHD Symptoms, Subtypes, and Comorbid Disorders in Clinically Referred Adults With ADHD. Journal of Clinical Psychiatry, 2009, 70, 1557-1562.	1.1	204
110	Prescribing Patterns for Treatment of Pediatric Bipolar Disorder in a Specialty Clinic. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 529-538.	0.7	21
111	Do Stimulants Protect Against Psychiatric Disorders in Youth With ADHD? A 10-Year Follow-up Study. Pediatrics, 2009, 124, 71-78.	1.0	215
112	Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Pediatrics, 2009, 155, 84-89.e1.	0.9	52
113	Updates on combination pharmacotherapy for adult ADHD. Current Attention Disorders Reports, 2009, 1, 111-115.	0.3	0
114	Family-based association study of the BDNF, COMT and serotonin transporter genes and DSM-IV bipolar-I disorder in children. BMC Psychiatry, 2009, 9, 2.	1.1	24
115	Posttraumatic stress disorder and substance use disorder in adolescent bipolar disorder. Bipolar Disorders, 2009, 11, 198-204.	1.1	22
116	Examination of concordance between maternal and youth reports in the diagnosis of pediatric bipolar disorder. Bipolar Disorders, 2009, 11, 298-306.	1.1	10
117	Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, doubleâ€blind treatment with psychostimulants, atomoxetine, or placebo. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2009, 50, 335-342.	3.1	35
118	An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents Who Are Atomoxetine Partial Responders: I. Effectiveness. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 485-492.	0.7	45
119	A Double-Blind, Randomized, Placebo-Controlled Trial of Divalproex Extended-Release in the Treatment of Bipolar Disorder in Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 519-532.	0.3	109
120	An Open Study of Adjunct OROS-Methylphenidate in Children Who Are Atomoxetine Partial Responders: II. Tolerability and Pharmacokinetics. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 493-499.	0.7	36
121	Comorbidity in Pediatric Bipolar Disorder. Child and Adolescent Psychiatric Clinics of North America, 2009, 18, 291-319.	1.0	55
122	Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1165-1172.	0.3	35
123	Retrospective Safety Analysis of Atomoxetine in Adult ADHD Patients with or without Comorbid Alcohol Abuse and Dependence. American Journal on Addictions, 2009, 18, 393-401.	1.3	24
124	Does Conduct Disorder Mediate the Development of Substance Use Disorders in Adolescents With Bipolar Disorder?. Journal of Clinical Psychiatry, 2009, 70, 259-265.	1.1	19
125	Concordance between Cigarette Smoking and the Modified Fagerström Tolerance Questionnaire in Controlled Studies of ADHD. American Journal on Addictions, 2008, 17, 491-496.	1.3	10
126	Cigarette Smoking Associated with Attention Deficit Hyperactivity Disorder. Journal of Pediatrics, 2008, 153, 414-419.e1.	0.9	88

#	Article	IF	Citations
127	A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions, 2008, 4, 24.	1.4	22
128	Varying the Wear Time of the Methylphenidate Transdermal System in Children With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 700-708.	0.3	54
129	Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: A controlled study. Drug and Alcohol Dependence, 2008, 95, 188-198.	1.6	92
130	Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug and Alcohol Dependence, 2008, 96, 145-154.	1.6	151
131	SUPRAVENTRICULAR TACHYCARDIA IN AN ADOLESCENT WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD). Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 219-220.	0.3	4
132	Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 21-31.	0.3	720
133	Effect of Prior Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder on Subsequent Risk for Cigarette Smoking and Alcohol and Drug Use Disorders in Adolescents. JAMA Pediatrics, 2008, 162, 916.	3.6	119
134	Stimulant Therapy and Risk for Subsequent Substance Use Disorders in Male Adults With ADHD: A Naturalistic Controlled 10-Year Follow-Up Study. American Journal of Psychiatry, 2008, 165, 597-603.	4.0	215
135	Familial Risk Analyses of Attention Deficit Hyperactivity Disorder and Substance Use Disorders. American Journal of Psychiatry, 2008, 165, 107-115.	4.0	97
136	Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2008, 28, S46-S53.	0.7	216
137	Pharmacotherapy of ADHD in Adults. CNS Spectrums, 2008, 13, 11-13.	0.7	37
138	Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder across the Life Span., 2008,, 667-685.		0
139	A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychological Medicine, 2007, 37, 1743-1752.	2.7	45
140	Hematologic and Blood Biochemistry Monitoring During Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder: 2-Year, Open-Label Study Results. Pediatrics, 2007, 120, e120-e128.	1.0	8
141	ADHD: Prevalence, Diagnosis, and Issues of Comorbidity. CNS Spectrums, 2007, 12, 1-5.	0.7	7
142	Dr. Wilens Replies. American Journal of Psychiatry, 2007, 164, 973-974.	4.0	1
143	Deriving phenotypes for molecular genetic studies of substance use disorders: A family study approach. Drug and Alcohol Dependence, 2007, 88, 244-250.	1.6	7
144	Meta-Analysis of Aggression or Hostility Events in Randomized, Controlled Clinical Trials of Atomoxetine for ADHD. Biological Psychiatry, 2007, 61, 713-719.	0.7	40

#	Article	IF	CITATIONS
145	Association of Bipolar and Substance Use Disorders in Parents of Adolescents With Bipolar Disorder. Biological Psychiatry, 2007, 62, 129-134.	0.7	30
146	Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition. Biochemical Pharmacology, 2007, 74, 1212-1223.	2.0	133
147	Do Individuals with ADHD Self-Medicate with Cigarettes and Substances of Abuse? Results from a Controlled Family Study of ADHD. American Journal on Addictions, 2007, 16, 14-23.	1.3	125
148	Substance Use among ADHD Adults: Implications of Late Onset and Subthreshold Diagnoses. American Journal on Addictions, 2007, 16, 24-34.	1.3	187
149	When ADHD and substance use disorders intersect: Relationship and treatment implications. Current Psychiatry Reports, 2007, 9, 408-414.	2.1	33
150	Impact of Substance Use Disorder on ADHD and Its Treatment. Journal of Clinical Psychiatry, 2007, 68, e20.	1.1	132
151	ADHD in Adults. Medical Psychiatry, 2007, , 273-290.	0.2	0
152	The nature of the relationship between attention-deficit/hyperactivity disorder and substance use. Journal of Clinical Psychiatry, 2007, 68 Suppl 11, 4-8.	1.1	39
153	Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth. Journal of Psychopharmacology, 2006, 20, 580-588.	2.0	97
154	Pharmacological Management of a Teen With Significant Alcohol Use and Depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1011-1015.	0.3	0
155	Treatment of ADHD With Stimulant Medications: Response to Nissen Perspective in The New England Journal of Medicine. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1147-1150.	0.3	31
156	Is Cigarette Smoking a Gateway to Alcohol and Illicit Drug Use Disorders? A Study of Youths with and without Attention Deficit Hyperactivity Disorder. Biological Psychiatry, 2006, 59, 258-264.	0.7	154
157	ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study. Biological Psychiatry, 2006, 59, 1065-1070.	0.7	110
158	Psychopathology in Females with Attention-Deficit/Hyperactivity Disorder: A Controlled, Five-Year Prospective Study. Biological Psychiatry, 2006, 60, 1098-1105.	0.7	144
159	Characteristics of Adolescents and Young Adults With ADHD Who Divert or Misuse Their Prescribed Medications. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 408-414.	0.3	214
160	Do Children and Adolescents With ADHD Respond Differently to Atomoxetine?. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 149-157.	0.3	53
161	Effects of Long-Term Atomoxetine Treatment for Young Children With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 919-927.	0.3	151
162	Pharmacological Management of a Youth With ADHD, Marijuana Use, and Mood Symptoms. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1138-1141.	0.3	5

#	Article	IF	CITATIONS
163	Family based association analysis of statistically derived quantitative traits for drug use in ADHD and the dopamine transporter gene. Addictive Behaviors, 2006, 31, 1088-1099.	1.7	9
164	Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: A 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 2006, 28, 266-279.	1.1	103
165	Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. Journal of Pediatrics, 2006, 149, 112-119.	0.9	88
166	Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder. JAMA Pediatrics, 2006, 160, 82.	3 . 6	144
167	Attention Deficit Hyperactivity Disorder and Substance Use Disorders. American Journal of Psychiatry, 2006, 163, 2059-2063.	4.0	54
168	Mixed Amphetamine Salts Extended-Release in the Treatment of Adult ADHD: $\langle i \rangle$ A Randomized, Controlled Trial $\langle i \rangle$. CNS Spectrums, 2006, 11, 625-639.	0.7	160
169	Combination pharmacotherapy for adult ADHD. Current Psychiatry Reports, 2006, 8, 409-415.	2.1	44
170	Stimulants and Sudden Death: What Is a Physician to Do?. Pediatrics, 2006, 118, 1215-1219.	1.0	85
171	Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychological Medicine, 2006, 36, 167-179.	2.7	677
172	A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents. American Journal of Psychiatry, 2006, 163, 1179-1186.	4.0	177
173	Once-Daily OROS® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 351-356.	0.7	34
174	An Open-Label Study of the Tolerability of Mixed Amphetamine Salts in Adults With Attention-Deficit/Hyperactivity Disorder and Treated Primary Essential Hypertension. Journal of Clinical Psychiatry, 2006, 67, 696-702.	1.1	43
175	Mechanism of action of agents used in attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 2006, 67 Suppl 8, 32-8.	1.1	36
176	Short- and Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended-Release in Adolescents With ADHD. CNS Spectrums, 2005, 10, 22-30.	0.7	20
177	Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Adults With ADHD. CNS Spectrums, 2005, 10, 35-43.	0.7	53
178	Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD. CNS Spectrums, 2005, 10, 16-25.	0.7	62
179	Influence of Parental SUD and ADHD on ADHD in their Offspring: Preliminary Results from a Pilot-controlled Family Study. American Journal on Addictions, 2005, 14, 179-187.	1.3	23
180	Characteristics of Adults with Attention Deficit Hyperactivity Disorder Plus Substance Use Disorder: The Role of Psychiatric Comorbidity. American Journal on Addictions, 2005, 14, 319-327.	1.3	70

#	Article	IF	Citations
181	An Open Trial of Adjunctive Donepezil in Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 947-955.	0.7	33
182	Assessing Cannabis Use in Adolescents and Young Adults: What Do Urine Screen and Parental Report Tell You?. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 742-750.	0.7	33
183	Pharmacotherapy of Adolescent Substance Use Disorders: AReview of the Literature. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 810-825.	0.7	34
184	The Clinical Dilemma of Using Medications in Substance-Abusing Adolescents and Adults with Attention-Deficit/Hyperactivity Disorder: What Does the Literature Tell Us?. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 787-798.	0.7	29
185	ADHD Treatment With Once-Daily OROS Methylphenidate: Final Results From a Long-Term Open-Label Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 1015-1023.	0.3	104
186	Attention-Deficit/Hyperactivity Disorder Among Adolescents: A Review of the Diagnosis, Treatment, and Clinical Implications. Pediatrics, 2005, 115, 1734-1746.	1.0	302
187	Short- and Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Children. Journal of Pediatrics, 2005, 147, 348-354.	0.9	76
188	Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behaviour Research and Therapy, 2005, 43, 831-842.	1.6	421
189	A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 2005, 57, 456-463.	0.7	344
190	Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biological Psychiatry, 2005, 57, 793-801.	0.7	165
191	Neuropsychological Functioning in Youth with Bipolar Disorder. Biological Psychiatry, 2005, 58, 540-548.	0.7	130
192	Blood Pressure Changes Associated With Medication Treatment of Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 2005, 66, 253-259.	1.1	122
193	Impact of Executive Function Deficits and Attention-Deficit/Hyperactivity Disorder (ADHD) on Academic Outcomes in Children Journal of Consulting and Clinical Psychology, 2004, 72, 757-766.	1.6	649
194	Risk of Substance Use Disorders in Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 1380-1386.	0.3	114
195	Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 2004, 27, 373-383.	0.7	64
196	Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatric Clinics of North America, 2004, 27, 283-301.	0.7	217
197	Attention-Deficit/Hyperactivity Disorder in Adults. JAMA - Journal of the American Medical Association, 2004, 292, 619.	3.8	244
198	Effects of Once-Daily Osmotic-Release Methylphenidate on Blood Pressure and Heart Rate in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2004, 24, 36-41.	0.7	72

#	Article	IF	Citations
199	A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into Adulthood. Journal of Clinical Psychiatry, 2004, 65, 1301-1313.	1.1	199
200	Impact of ADHD and its treatment on substance abuse in adults. Journal of Clinical Psychiatry, 2004, 65 Suppl 3, 38-45.	1.1	44
201	ADHD Treatment With Once-Daily OROS Methylphenidate: Interim 12-Month Results From a Long-Term Open-Label Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 424-433.	0.3	132
202	An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biological Psychiatry, 2003, 54, 9-16.	0.7	76
203	Can adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults. Biological Psychiatry, 2003, 54, 1-8.	0.7	85
204	Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder. Drugs, 2003, 63, 2395-2411.	4.9	78
205	Does Stimulant Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later Substance Abuse? A Meta-analytic Review of the Literature. Pediatrics, 2003, 111, 179-185.	1.0	837
206	A Systematic Chart Review of the Nature of Psychiatric Adverse Events in Children and Adolescents Treated with Selective Serotonin Reuptake Inhibitors. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 143-152.	0.7	94
207	Patterns of Comorbidity and Dysfunction in Clinically Referred Preschool and School-Age Children with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 2003, 13, 495-505.	0.7	71
208	Current concepts in the validity, diagnosis and treatment of paediatric bipolar disorder. International Journal of Neuropsychopharmacology, 2003, 6, 293-300.	1.0	43
209	Does the medicating ADHD increase or decrease the risk for later substance abuse?. Revista Brasileira De Psiquiatria, 2003, 25, 127-128.	0.9	26
210	Influence of Gender on Attention Deficit Hyperactivity Disorder in Children Referred to a Psychiatric Clinic. American Journal of Psychiatry, 2002, 159, 36-42.	4.0	679
211	Fluoxetine Pharmacokinetics in Pediatric Patients. Journal of Clinical Psychopharmacology, 2002, 22, 568-575.	0.7	57
212	Patterns of Psychopathology and Dysfunction in Clinically Referred Preschoolers. Journal of Developmental and Behavioral Pediatrics, 2002, 23, S31-S36.	0.6	87
213	Psychiatric Comorbidity and Functioning in Clinically Referred Preschool Children and School-Age Youths With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 262-268.	0.3	319
214	Attention Deficit/Hyperactivity Disorder Across the Lifespan. Annual Review of Medicine, 2002, 53, 113-131.	5.0	458
215	A Family Study of the High-Risk Children of Opioid- and Alcohol-Dependent Parents. American Journal on Addictions, 2002, 11, 41-51.	1.3	54
216	A family study of psychiatric comorbidity in girls and boys with attention-deficit/hyperactivity disorder. Biological Psychiatry, 2001, 50, 586-592.	0.7	54

#	Article	IF	Citations
217	Efficacy of a Mixed Amphetamine Salts Compound in Adults With Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 2001, 58, 775.	13.8	236
218	A review of the pharmacotherapy of adults with Attention-Deficit/ Hyperactivity Disorder. Journal of Attention Disorders, 2001, 5, 189-202.	1.5	166
219	A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults. American Journal of Psychiatry, 2001, 158, 282-288.	4.0	258
220	Family Study of Girls With Attention Deficit Hyperactivity Disorder. American Journal of Psychiatry, 2000, 157, 1077-1083.	4.0	148
221	Is Bipolar Disorder a Risk for Cigarette Smoking in ADHD Youth?. American Journal on Addictions, 2000, 9, 187-195.	1.3	25
222	The Stimulants Revisited. Child and Adolescent Psychiatric Clinics of North America, 2000, 9, 573-603.	1.0	119
223	Pemoline Treatment of Adolescents with Attention Deficit Hyperactivity Disorder: A Short-Term Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 205-216.	0.7	28
224	Therapeutic Dilemmas in the Pharmacotherapy of Bipolar Depression in the Young. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 185-192.	0.7	93
225	Adjunctive Donepezil in Attention Deficit Hyperactivity Disorder Youth: Case Series. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 217-222.	0.7	50
226	Pediatric mania: a developmental subtype of bipolar disorder?. Biological Psychiatry, 2000, 48, 458-466.	0.7	210
227	A Controlled Study of Nortriptyline in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 193-204.	0.7	84
228	The 4-Year Course of Tic Disorders in Boys With Attention-Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 1999, 56, 842.	13.8	100
229	Absence of Effect of Stimulants on the Pharmacokinetics of Desipramine in Children. Pharmacotherapy, 1999, 19, 746-752.	1.2	21
230	Systematic Chart Review of the Pharmacologic Treatment of Comorbid Attention Deficit Hyperactivity Disorder in Youth with Bipolar Disorder. Journal of Child and Adolescent Psychopharmacology, 1999, 9, 247-256.	0.7	89
231	Antidepressant treatment of juvenile depression. International Journal of Psychiatry in Clinical Practice, 1999, 3, 171-179.	1.2	2
232	Clinical Correlates of ADHD in Females: Findings From a Large Group of Girls Ascertained From Pediatric and Psychiatric Referral Sources. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 966-975.	0.3	332
233	Risk for Substance Use Disorders in Youths With Child- and Adolescentâ€Onset Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 680-685.	0.3	130
234	Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder. Pediatrics, 1999, 104, e20-e20.	1.0	418

#	Article	IF	Citations
235	Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 1999, 19, 257-264.	0.7	50
236	Cognitive Therapy in the Treatment of Adults With ADHD: A Systematic Chart Review of 26 Cases. Journal of Cognitive Psychotherapy, 1999, 13, 215-226.	0.2	75
237	Does ADHD Affect the Course of Substance Abuse?: <i>Findings From a Sample of Adults With and Without ADHD</i> . American Journal on Addictions, 1998, 7, 156-163.	1.3	62
238	Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?. Biological Psychiatry, 1998, 44, 269-273.	0.7	264
239	Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder. American Journal of Psychiatry, 1998, 155, 693-695.	4.0	308
240	Familial Risk Analysis of the Association Between Attention-Deficit/Hyperactivity Disorder and Psychoactive Substance Use Disorders. JAMA Pediatrics, 1998, 152, 945-51.	3.6	23
241	Does ADHD Affect the Course of Substance Abuse? Findings From a Sample of Adults With and Without ADHD. American Journal on Addictions, 1998, 7, 156-163.	1.3	41
242	Growth Deficits in Children With Attention Deficit Hyperactivity Disorder. Pediatrics, 1998, 102, 501-506.	1.0	74
243	Case Study: Adverse Effects of Smoking Marijuana While Receiving Tricyclic Antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 45-48.	0.3	53
244	Clinical Characteristics of Psychiatrically Referred Adolescent Outpatients With Substance Use Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 941-947.	0.3	102
245	Is ADHD a Risk Factor for Psychoactive Substance Use Disorders? Findings From a Four-Year Prospective Follow-up Study. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 21-29.	0.3	466
246	Associations Between ADHD and Psychoactive Substance Use Disorders. American Journal on Addictions, 1997, 6, 318-329.	1.3	43
247	Attention Deficit Hyperactivity Disorder (ADHD) is Associated with Early Onset Substance Use Disorders. Journal of Nervous and Mental Disease, 1997, 185, 475-482.	0.5	253
248	Associations Between ADHD and Psychoactive Substance use Disorders: Findings from a Longitudinal Study of High-Risk Siblings of ADHD Children. American Journal on Addictions, 1997, 6, 318-329.	1.3	51
249	Growth Deficits in ADHD Children Revisited: Evidence for Disorder-Associated Growth Delays?. Journal of the American Academy of Child and Adolescent Psychiatry, 1996, 35, 1460-1469.	0.3	217
250	Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 1996, 35, 409-432.	0.3	745
251	Attention-Deficit Hyperactivity Disorder and the Psychoactive Substance Use Disorders. Child and Adolescent Psychiatric Clinics of North America, 1996, 5, 73-91.	1.0	32
252	A Systematic Assessment of Tricyclic Antidepressants in the Treatment of Adult Attention-Deficit Hyperactivity Disorder. Journal of Nervous and Mental Disease, 1995, 183, 48-49.	0.5	67

#	Article	IF	Citations
253	Pilot Study of Behavioral and Emotional Disturbances in the High-Risk Children of Parents with Opioid Dependence. Journal of the American Academy of Child and Adolescent Psychiatry, 1995, 34, 779-785.	0.3	84
254	Are Attention-Deficit Hyperactivity Disorder and the Psychoactive Substance Use Disorders Really Related?. Harvard Review of Psychiatry, 1995, 3, 160-162.	0.9	22
255	Combined Pharmacotherapy: An Emerging Trend in Pediatric Psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry, 1995, 34, 110-112.	0.3	101
256	Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 1995, 15, 270-279.	0.7	105
257	Comorbidity of Attention-Deficit Hyperactivity and Psychoactive Substance Use Disorders. Psychiatric Services, 1994, 45, 421-435.	1.1	30
258	Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatry Research, 1994, 53, 13-29.	1.7	267
259	A Public Dualâ€Diagnosis Detoxification Unit: <i>Part III: Shortâ€Term Efficacy of Treatment</i> Journal on Addictions, 1994, 3, 194-203.	1.3	2
260	The child and adolescent offspring of drug- and alcohol-dependent parents. Current Opinion in Psychiatry, 1994, 7, 319-323.	3.1	9
261	A Public Dual Diagnosis Detoxification Unit. American Journal on Addictions, 1993, 2, 181-193.	1.3	7
262	Psychopathology in Preadolescent Children at High Risk for Substance Abuse: A Review of the Literature. Harvard Review of Psychiatry, 1993, 1, 207-218.	0.9	41
263	The Stimulants. Psychiatric Clinics of North America, 1992, 15, 191-222.	0.7	159
264	Molecular genetics of ADHD., 0,, 174-197.		0
265	Stimulant medication in children and adolescents. , 0, , 245-258.		0
266	Assessment and treatment of depressive disorders in adults with ADHD., 0,, 82-97.		0
267	Beyond DSM-IV diagnostic criteria. , 0, , 53-62.		1
268	History of attention-deficit hyperactivity disorder (ADHD)., 0,, 1-15.		16
269	Preschool ADHD treatment. , 0, , 318-326.		0
270	The epidemiology and societal burden of ADHD. , 0, , 24-41.		1

#	Article	lF	CITATIONS
271	Functional impairment in ADHD., 0,, 42-52.		3
272	Attention-deficit hyperactivity disorder and the substance use disorders in ADHD., 0,, 111-122.		2
273	Neuropsychological testing., 0,, 210-223.		O
274	Non-stimulant treatment of ADHD., 0,, 259-275.		1
275	Pharmacotherapy of ADHD in adults. , 0, , 276-297.		9
276	Complementary and alternative treatments for pediatric and adult ADHD., 0,, 307-317.		2
277	ADHD and smoking. , 0, , 327-342.		O
278	ADHD and tic disorders., 0,, 343-352.		2
279	Sustainable change., 0,, 353-365.		1
280	College students with ADHD., 0,, 366-377.		5
281	Catecholamine influences on prefrontal cortex circuits and function., 0,, 161-173.		0
282	Assessment of ADHD in children and adolescents. , 0, , 233-244.		1
283	Mimics of ADHD., 0,, 150-160.		2
284	Psychosocial treatment of ADHD in adults. , 0, , 298-306.		2
285	Bipolar disorder and ADHD. , 0, , 72-81.		1
286	Neuroimaging of ADHD., 0,, 198-209.		0